iShares Biotechnology ETF
IBB
IBB
865 hedge funds and large institutions have $4.59B invested in iShares Biotechnology ETF in 2024 Q4 according to their latest regulatory filings, with 115 funds opening new positions, 208 increasing their positions, 322 reducing their positions, and 111 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
865
Holders Change
-18
Holders Change %
-2.04%
% of All Funds
11.52%
Holding in Top 10
11
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+10%
% of All Funds
0.15%
New
115
Increased
208
Reduced
322
Closed
111
Calls
$424M
Puts
$829M
Net Calls
-$404M
Net Calls Change
-$89.9M
Top Buyers
| 1 |
1
Jane Street
New York
|
$258M |
| 2 |
2
Bank of America
Charlotte,
North Carolina
|
$990M |
| 3 |
3
Barclays
London,
United Kingdom
|
$89.7M |
| 4 |
4
Morgan Stanley
New York
|
$460M |
| 5 |
5
UBS Group
Zurich,
Switzerland
|
$146M |
Top Sellers
| 1 |
1
BNP Paribas Financial Markets
Paris,
France
|
$181M |
| 2 |
2
Goldman Sachs
New York
|
$113M |
| 3 |
3
Royal Bank of Canada
Toronto,
Ontario, Canada
|
$159M |
| 4 |
4
JPMorgan Chase & Co
New York
|
$41.6M |
| 5 |
5
LPL Financial
San Diego,
California
|
$55.5M |
